Long-acting beta-agonists (LTBAs) received a Black Box Warning from the U.S. Food and Drug Administration due to the:

Question

Quizplus · Accepted Answer

Long-acting beta-agonists (LTBAs) have received a Black Box Warning due to the increased risk of asthma-related deaths when used for the treatment of asthma. This warning was issued by the U.S. Food and Drug Administration, and it advises healthcare providers to use LTBAs only when they are necessary and in combination with other medications, such as inhaled corticosteroids. Patients who use LTBAs should be closely monitored for signs of worsening symptoms and should seek medical attention if they experience difficulty breathing or other serious side effects.

Long-Acting Beta-Agonists (LTBAs) Received a Black Box Warning from the U.S